ALS therapy target: Integrin that spurs immune cells to ‘eat’ neurons
A “velcro-like” protein called alpha-5 integrin consistently is found at high levels in immune cells near motor neurons being damaged…
Articles by Margarida Maia, PhD
InSilicoTrials, Axoltis partner to work on potential ALS therapy
InSilicoTrials and Axoltis Pharma are teaming up to advance the development of NX210c, the latter’s lead candidate for…
Researcher awarded $10K to advance work on ALS therapy
A professor at Massachusetts General Hospital and Harvard Medical School was awarded $10,000 by Mass General Brigham (MGB) for…
ATH-1105 protects against common ALS, FTD disease mechanisms
Athira Pharma’s experimental therapy ATH-1105 shows anti-inflammatory and neuroprotective effects, promoting neuron growth and reducing damage associated with mechanisms…
Study uncovers 2 therapies to help target autoimmune inflammation
Dimethyl fumarate (DMF) — an oral medication approved for multiple sclerosis — and H-151, an experimental treatment, can suppress…
Slower ALS progression evident with lower NfL levels: NurOwn trial
NurOwn, an experimental treatment, significantly lowered neurofilament light chain (NfL) levels in the spinal fluid, a marker of nerve…
Potential ALS therapy, VRG50635, found to be safe in healthy adults
VRG50635, an experimental oral therapy being developed by Verge Genomics for amyotrophic lateral sclerosis (ALS), was found to…
EMA committee leaning toward not recommending AMX0035 approval
A committee of the European Medicines Agency (EMA) is leaning toward not recommending a conditional approval of Amylyx Pharmaceuticals’…
Pison’s AI-powered technology may help identify early ALS
A new technology powered by artificial intelligence (AI) may one day help doctors diagnose people in the early stages of…
ALS costs may reach $1.02B each year in US, study finds
There are currently up to 18,000 people living with amyotrophic lateral sclerosis (ALS) in the U.S., with national costs…